Lucrative Conference: Benda Recognizes $1.3 Million For Gendicine Order
This article was originally published in PharmAsia News
Executive Summary
SHANGAHI - Benda has recognized $1.3 million in revenues from an order worth $3.8 million placed at a recent conference for its cancer gene therapy Gendicine, the company announced Dec 5